Johnson & Johnson and Legend Biotech’s Carvykti showed it could prevent disease progression in the earlier treatment of multiple myeloma, now results are showing that a single dose slashed the death risk by 45% compared with two traditional combination treatments in myeloma patients who had received at least one prior line of therapy, according to an update of the phase 3 CARTITUDE-4 trial.
Click here to read the entire article.